دورية أكاديمية
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
| العنوان: | Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial |
|---|---|
| المؤلفون: | Ascierto P. A., Mandala' M., Ferrucci P. F., Guidoboni M., Rutkowski P., Ferraresi V., Arance A., Guida M., Maiello E., Gogas H., Richtig E., Fierro M. T., Lebbe C., Helgadottir H., Queirolo P., Spagnolo F., Tucci M., Del Vecchio M., Gonzales Cao M., Minisini A. M., De Placido S., Sanmamed M. F., Mallardo D., Curvietto M., Melero I., Palmieri G., Grimaldi A. M., Giannarelli D., Dummer R., Chiarion Sileni V. |
| المساهمون: | Ascierto, P. A., Mandala', M., Ferrucci, P. F., Guidoboni, M., Rutkowski, P., Ferraresi, V., Arance, A., Guida, M., Maiello, E., Gogas, H., Richtig, E., Fierro, M. T., Lebbe, C., Helgadottir, H., Queirolo, P., Spagnolo, F., Tucci, M., Del Vecchio, M., Gonzales Cao, M., Minisini, A. M., De Placido, S., Sanmamed, M. F., Mallardo, D., Curvietto, M., Melero, I., Palmieri, G., Grimaldi, A. M., Giannarelli, D., Dummer, R., Chiarion Sileni, V. |
| سنة النشر: | 2023 |
| المجموعة: | IRIS Università degli Studi di Perugia |
| الوصف: | PURPOSELimited prospective data are available on sequential immunotherapy and BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma.METHODSSECOMBIT is a randomized, three-arm, noncomparative phase II trial (ClinicalTrials.gov identifier: NCT02631447). Patients with untreated, metastatic BRAFV600-mutant melanoma from 37 sites in nine countries were randomly assigned to arm A (encorafenib [450 mg orally once daily] plus binimetinib [45 mg orally twice daily] until progressive disease [PD] -> ipilimumab plus nivolumab [ipilimumab 3 mg/kg once every 3 weeks and nivolumab 1 mg/kg once every 3 weeks × four cycles -> nivolumab 3 mg/kg every 2 weeks]), arm B [ipilimumab plus nivolumab until PD -> encorafenib plus binimetinib], or arm C (encorafenib plus binimetinib for 8 weeks -> ipilimumab plus nivolumab until PD -> encorafenib plus binimetinib). The primary end point was overall survival (OS) at 2 years. Secondary end points included total progression-free survival, 3-year OS, best overall response rate, duration of response, and biomarkers in the intent-to-treat population. Safety was analyzed throughout sequential treatment in all participants who received at least one dose of study medication.RESULTSA total of 209 patients were randomly assigned (69 in arm A, 71 in arm B, and 69 in arm C). At a median follow-up of 32.2 (interquartile range, 27.9-41.6) months, median OS was not reached in any arm and more than 30 patients were alive in all arms. Assuming a null hypothesis of median OS of ≤ 15 months, the OS end point was met for all arms. The 2-year and 3-year OS rates were 65% (95% CI, 54 to 76) and 54% (95% CI, 41 to 67) in arm A, 73% (95% CI, 62 to 84) and 62% (95% CI, 48 to 76) in arm B, and 69% (95% CI, 59 to 80) and 60% (95% CI, 58 to 72) in arm C. No new safety signals emerged.CONCLUSIONSequential immunotherapy and targeted therapy provide clinically meaningful survival benefits for patients with BRAFV600-mutant melanoma. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/36049147; info:eu-repo/semantics/altIdentifier/wos/WOS:000921267800011; volume:41; issue:2; firstpage:212; lastpage:221; numberofpages:10; journal:JOURNAL OF CLINICAL ONCOLOGY; https://hdl.handle.net/11391/1566842Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85139981623 |
| DOI: | 10.1200/JCO.21.02961 |
| الإتاحة: | https://doi.org/10.1200/JCO.21.02961Test https://hdl.handle.net/11391/1566842Test |
| رقم الانضمام: | edsbas.AD2D8CCE |
| قاعدة البيانات: | BASE |
| DOI: | 10.1200/JCO.21.02961 |
|---|